HK1188442A1 - 氮雜 中氮茚衍生物及其藥物用途 - Google Patents
氮雜 中氮茚衍生物及其藥物用途Info
- Publication number
- HK1188442A1 HK1188442A1 HK14100528.5A HK14100528A HK1188442A1 HK 1188442 A1 HK1188442 A1 HK 1188442A1 HK 14100528 A HK14100528 A HK 14100528A HK 1188442 A1 HK1188442 A1 HK 1188442A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- aza
- pharmaceutical use
- indolizine derivative
- indolizine
- derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010219600 | 2010-09-29 | ||
PCT/JP2011/072201 WO2012043638A1 (ja) | 2010-09-29 | 2011-09-28 | (アザ)インドリジン誘導体及びその医薬用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1188442A1 true HK1188442A1 (zh) | 2014-05-02 |
Family
ID=45893077
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK14100528.5A HK1188442A1 (zh) | 2010-09-29 | 2014-01-17 | 氮雜 中氮茚衍生物及其藥物用途 |
HK15107096.1A HK1206360A1 (zh) | 2010-09-29 | 2015-07-24 | 氮雜 中氮茚衍生物及其藥物用途 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15107096.1A HK1206360A1 (zh) | 2010-09-29 | 2015-07-24 | 氮雜 中氮茚衍生物及其藥物用途 |
Country Status (9)
Country | Link |
---|---|
US (1) | US9643969B2 (zh) |
EP (1) | EP2623505B1 (zh) |
JP (1) | JP5906191B2 (zh) |
KR (1) | KR20130099064A (zh) |
CN (2) | CN103221412B (zh) |
CA (1) | CA2811773A1 (zh) |
ES (1) | ES2549926T3 (zh) |
HK (2) | HK1188442A1 (zh) |
WO (1) | WO2012043638A1 (zh) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9458164B2 (en) | 2013-03-11 | 2016-10-04 | Bristol-Myers Squibb Company | Pyrrolopyridazines as potassium ion channel inhibitors |
US9403834B2 (en) | 2013-03-11 | 2016-08-02 | Bristol-Myers Squibb Company | Pyrrolotriazines as potassium ion channel inhibitors |
SG10201806846RA (en) | 2014-02-13 | 2018-09-27 | Incyte Corp | Cyclopropylamines as lsd1 inhibitors |
US9493442B2 (en) | 2014-02-13 | 2016-11-15 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
PT3105218T (pt) | 2014-02-13 | 2019-12-05 | Incyte Corp | Ciclopropilaminas como inibidores de lsd1 |
US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
US9695167B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors |
TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為lsd1抑制劑之咪唑并吡啶及咪唑并吡嗪 |
US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
TWI714567B (zh) | 2015-04-03 | 2021-01-01 | 美商英塞特公司 | 作為lsd1抑制劑之雜環化合物 |
BR112018002553A8 (pt) | 2015-08-12 | 2023-01-24 | Incyte Corp | Sais de um inibidor de lsd1 |
JP6859323B2 (ja) | 2015-09-02 | 2021-04-14 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. | カルボキシ置換(ヘテロ)芳香環誘導体並びにその調製方法及び使用 |
JP6898330B2 (ja) * | 2015-12-28 | 2021-07-07 | シャンハイ フォチョン ファーマシューティカル カンパニー リミテッド | インドリジン誘導体、組成物、及び使用方法 |
CN114456176B (zh) | 2016-03-28 | 2024-08-30 | 因赛特公司 | 作为tam抑制剂的吡咯并三嗪化合物 |
SG11201809299QA (en) | 2016-04-22 | 2018-11-29 | Incyte Corp | Formulations of an lsd1 inhibitor |
US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
CN111943957B (zh) * | 2019-05-17 | 2023-01-06 | 中国医学科学院药物研究所 | 喹啉甲酰胺类化合物及其制备方法和用途 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ193926A (en) | 1979-07-06 | 1984-05-31 | Labaz Sanofi Nv | 2-(alkyl or phenyl)-3(4-hydroxybenzoyl)indolizines |
JP5222561B2 (ja) * | 2005-10-07 | 2013-06-26 | キッセイ薬品工業株式会社 | 含窒素芳香族複素環化合物およびそれを含有する医薬組成物 |
ES2401099T3 (es) | 2005-11-02 | 2013-04-16 | Bayer Intellectual Property Gmbh | Pirrolo[2,1-F] [1,2,4]-triazin-4-ilaminas como inhibidores de la quinasa IGF-1R para el tratamiento del cáncer y de otras enfermedades hiperproliferativas |
BRPI0810524B8 (pt) * | 2007-04-11 | 2021-05-25 | Kissei Pharmaceutical | derivado de (aza)indol, inibidor de xantina oxidase e composição farmacêutica compreendendo o dito derivado |
JP5330990B2 (ja) * | 2007-04-11 | 2013-10-30 | キッセイ薬品工業株式会社 | 含窒素複素環化合物およびそれを含有する医薬組成物 |
CA2755132C (en) * | 2009-03-31 | 2018-02-13 | Kissei Pharmaceutical Co., Ltd. | Indolizine derivative and use thereof for medical purposes |
-
2011
- 2011-09-28 US US13/824,147 patent/US9643969B2/en not_active Expired - Fee Related
- 2011-09-28 WO PCT/JP2011/072201 patent/WO2012043638A1/ja active Application Filing
- 2011-09-28 JP JP2012536511A patent/JP5906191B2/ja not_active Expired - Fee Related
- 2011-09-28 EP EP11829191.3A patent/EP2623505B1/en not_active Not-in-force
- 2011-09-28 CN CN201180055764.5A patent/CN103221412B/zh not_active Expired - Fee Related
- 2011-09-28 CN CN201510005098.4A patent/CN104592224B/zh not_active Expired - Fee Related
- 2011-09-28 CA CA2811773A patent/CA2811773A1/en not_active Abandoned
- 2011-09-28 KR KR1020137006949A patent/KR20130099064A/ko not_active Application Discontinuation
- 2011-09-28 ES ES11829191.3T patent/ES2549926T3/es active Active
-
2014
- 2014-01-17 HK HK14100528.5A patent/HK1188442A1/zh not_active IP Right Cessation
-
2015
- 2015-07-24 HK HK15107096.1A patent/HK1206360A1/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US9643969B2 (en) | 2017-05-09 |
EP2623505A1 (en) | 2013-08-07 |
KR20130099064A (ko) | 2013-09-05 |
EP2623505A4 (en) | 2013-10-02 |
CN104592224B (zh) | 2016-08-03 |
ES2549926T3 (es) | 2015-11-03 |
HK1206360A1 (zh) | 2016-01-08 |
JPWO2012043638A1 (ja) | 2014-02-24 |
CA2811773A1 (en) | 2012-04-05 |
CN104592224A (zh) | 2015-05-06 |
CN103221412B (zh) | 2015-08-19 |
JP5906191B2 (ja) | 2016-04-20 |
CN103221412A (zh) | 2013-07-24 |
WO2012043638A1 (ja) | 2012-04-05 |
US20130217878A1 (en) | 2013-08-22 |
EP2623505B1 (en) | 2015-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1206360A1 (zh) | 氮雜 中氮茚衍生物及其藥物用途 | |
HK1165793A1 (zh) | 中氮茚衍生物及其醫藥用途 | |
EP2600876A4 (en) | METHODS AND APPARATUSES FOR COMBINED DRUG DELIVERY | |
ZA201300100B (en) | Indolizine derivatives,process for the preparation thereof and therapeutic use thereof | |
GB201010193D0 (en) | Medicinal use | |
EP2634176A4 (en) | PYRIDINE DERIVATIVE AND MEDICINAL AGENT | |
HK1169960A1 (en) | Pharmaceutical formulation | |
EP2583651A4 (en) | ROLLING CHAIR AND BED | |
EP2718283A4 (en) | INDAZOLE AND PYRROLOPYRIDINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | |
AP3441A (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
GB2486567B (en) | Pharmaceutical formulation | |
IL228436A0 (en) | Pyridopyrazine history and their use | |
PT2521445T (pt) | Formulação e utilização da mesma | |
IL226003A0 (en) | Derivation of trans-2-decenoic acid and a pharmaceutical agent containing it | |
IL223254A0 (en) | Use of diatomaceous earth in the pharmaceutical industry | |
EP2560614A4 (en) | PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THEIR ADMINISTRATION | |
IL221087A (en) | Pharmacy or nutritional composition | |
IL223707A0 (en) | N-hydroxyformamide derivative and medicament containing same | |
IL226388A0 (en) | New indolizine derivatives, their preparation and medical use | |
GB201002451D0 (en) | Pharmaceutical comopitions and devices | |
GB201012660D0 (en) | Inhaler and formulation | |
GB201112578D0 (en) | Pharmaceutical preparation and use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20191002 |